229 / 510
Cuidados
Continuos
228
BIBLIOGRAFÍA
Sawyers C. Targeted cancer therapy. Nature, 2004; 432: 294-297.
Widakowich C, De Castro G, Azambuja E
,,
Dinh P, Awada AReview: Side Effects of ApprovedMolecular
Targeted Therapies in Solid Cancers. Oncologist 2007; 12:1443-55
Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during
therapy with epidermal growth factor receptor inhibitors. Annals of Oncology, 2005; 16: 1425-1433.
Pinto C, Barren CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D et al. Management of Skin
Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy.
Oncologist 2011;16:228-238
Lynch T, Kim S, Eaby B, Garey J, West D, Lacouture E. Epidermal growth factor receptor inhibitor-
associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist, 2007; 12:
610-621.
CappuzzoF, Bartolini S, Ceresoli GL, Tamberi S, SpreaficoA, LombardoLet al. Efficacy and tolerability
of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J
Cancer, 2004; 90: 82-86.
Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia.
J Natl Cancer Inst, 2005; 97: 1221-1224.
Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y et al. Severe acute interstitial pneumonia
and gefitinib. Lancet, 2003; 361: 137-139.
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al. TRIBUTE: a phase
III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in
advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 5892-5899.
Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis, 2004;
7: 193-201
Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients
with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008; 9: 117-123.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, HeimW et al. Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:
2335-2342..
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al. CORRECT Study Group.
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an
international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303-312
Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with
the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with
metastatic renal cell carcinoma. Eur Urol 2008; 53:918-930
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus
interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for
metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc
J. 2007;1(2 Suppl):S41-54.
Escudier B and Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D.
2011;11(2):113-26
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced
or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28;1061-
1068
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.